Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

RFI – Development of Animal Models for Antibacterial Drug Development

by Global Biodefense Staff
January 5, 2017
RFI FDA Narrow-Spectrum Antibacterials

RFI FDA Narrow-Spectrum AntibacterialsThe FDA’s Center for Drug Evaluation and Research is seeking input from the public and private sectors on research ideas to facilitate the development of drugs to help mitigate antibiotic resistance.

There is interest in studying therapies for serious bacterial infections that are active against only a single species of bacteria. This is particularly challenging due to rarity of the pathogen of interest, the need to immediately begin antibacterial drug treatment, and the delay in availability of information regarding the antibacterial susceptibility of an isolated pathogen.

FDA is interested in research to advance regulatory science to facilitate the development of narrow-spectrum antibacterial drugs such as those that are active against only a single species of bacteria that may not occur frequently in any one type of infection/site of infection.  When the species occurs infrequently, performing clinical trials can be extremely challenging.  Therefore, animal models of infection may be useful to explore the activity of a candidate antibacterial drug and may help to predict the likelihood of human clinical response.

Additional scientific work to evaluate the current state of animal models of infection and evaluate potential animal models that may predict response in humans could advance the development of antibacterial drugs targeting a single species.

FDA is particularly interested in infections due to Acinetobacter baumanii and Pseudomonas aeruginosa because there are limited therapeutic options to treat some patients with serious infections caused by these bacteria and it is difficult to enroll an adequate number of patients to conduct clinical trials.

Further details are available via Solicitation Number: FDA-RFI-1177696. Responses to this RFI will be accepted until February 1, 2017.

Tags: Animal ModelsRFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC